Quantcast

Latest Eastern Cooperative Oncology Group Stories

2014-09-10 16:25:08

Stage set to determine if drugs called tyrosine kinase inhibitors will extend the lives of patients with the high-risk acute lymphoblastic leukemia subtype; pediatric clinical trial scheduled to open by early 2015 MEMPHIS, Tenn., Sept. 10, 2014 /PRNewswire-USNewswire/ -- More than one-quarter of young adults with the most common form of acute lymphoblastic leukemia (ALL) have a high-risk subtype with a poor prognosis and may benefit from drugs widely used to treat other types of...

2014-09-02 12:28:59

ZION, Ill., Sept. 2, 2014 /PRNewswire-USNewswire/ -- Cancer Treatment Centers of America at Midwestern Regional Medical Center has been recognized by the Quality Oncology Practice Initiative (QOPI®) Certification Program, an affiliate of the American Society of Clinical Oncology (ASCO), for meeting the highest standards for quality cancer care. The QOPI® Certification Program (QCP(TM)) provides a three-year certification for outpatient hematology-oncology practices that meet the...

2014-08-18 23:02:59

The anti-cancer drug Xalkori® is being investigated by the ECOG-ACRIN Cancer Research Group in E4512, a phase III trial. Philadelphia, PA (PRWEB) August 18, 2014 People diagnosed with early-stage non-squamous non-small cell lung cancer whose tumors have an altered ALK gene now have the opportunity to participate in a new phase III clinical trial, ECOG-ACRIN announced today. The trial will determine if Xalkori® (generic name crizotinib, an ALK-inhibitor), when used after...

2014-07-25 23:01:44

Researchers at the ECOG-ACRIN Cancer Research Group say comprehensive informed consent is likely the key to preventing undue anxiety over lung screenings. Philadelphia, PA (PRWEB) July 25, 2014 A new study of participants in the National Lung Screening Trial (NLST), the results of which are published today in Cancer, found evidence that men and women between the ages of 55 and 74 who had an abnormal finding on a lung cancer screening test did not experience more anxiety or reduced quality...

2014-06-30 23:10:00

Entinostat is being investigated in patients with advanced hormone receptor-positive breast cancer by the ECOG-ACRIN Cancer Research Group in trial E2112. PHILADELPHIA, Pa. and WALTHAM, Mass. (PRWEB) June 30, 2014 The ECOG-ACRIN Cancer Research Group and Syndax Pharmaceuticals Inc. announced today enrollment of the first patient in E2112, a randomized phase III clinical trial of Syndax’s histone deacetylase (HDAC) inhibitor, entinostat, for the treatment of patients with advanced breast...

2014-05-06 23:06:23

Expands Relationship of Innovation and Efficiencies (PRWEB) May 06, 2014 Florida Cancer Specialists & Research Institute (FCS), one of the largest cancer care providers in the United States, announced it will now be sourcing all of its chemotherapeutic and supportive therapy products from Oncology Supply. The agreement will go into effect immediately. "We're very pleased with the new contract and continuing our long-term partnership with Oncology Supply and International...

2014-04-10 23:27:08

In CHAMPS Oncology's most recent blog post, Celebrating National Cancer Registrars Week, Toni Hare shares her thoughts on the topic. Cleveland, OH (PRWEB) April 10, 2014 In CHAMPS Oncology's most recent blog post, Celebrating National Cancer Registrars Week, Toni Hare shares her thoughts on the topic. Many people have known someone who has been affected by cancer in a way that made her first pursue a career in the cancer registry profession. Since then, her work has allowed her to...

2014-03-20 23:22:02

Entinostat is being investigated in patients with advanced hormone receptor-positive breast cancer by the ECOG-ACRIN Cancer Research Group in its latest trial, E2112. Philadelphia, PA, and Waltham, MA (PRWEB) March 20, 2014 The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and Syndax Pharmaceuticals, Inc., announced today that patient recruitment has begun for E2112, a randomized phase III clinical trial of Syndax’s entinostat in treatment of patients with advanced breast cancer. The...

2014-03-03 23:22:56

Allegheny Health Network Cancer Institute has earned QOPI® (Quality Oncology Practice Initiative) Certification for its commitment to achieving excellence and ongoing quality improvement in its medical oncology, hematology and cell transplant programs. Allegheny is one of just nine cancer centers in Pennsylvania to earn this distinction. Pittsburgh, PA (PRWEB) March 03, 2014 Allegheny Health Network Cancer Institute has earned QOPI® (Quality Oncology Practice Initiative)...

2014-02-13 08:30:49

WALTHAM, Mass., Feb. 13, 2014 /PRNewswire/ -- Syndax Pharmaceuticals, Inc., today announced that the Division of Cancer Treatment and Diagnosis (DCTD) of the National Cancer Institute (NCI) has reached a special protocol assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA) for the planned pivotal Phase 3 trial of entinostat in patients with advanced breast cancer. The Phase 3 trial, expected to begin in the first half of this year, is intended to evaluate...


Word of the Day
omadhaun
  • A fool; a simpleton: a term of abuse common in Ireland and to a less extent in the Gaelic-speaking parts of Scotland.
This word is partly Irish in origin.